Ann: FY24 Results - Record Harvest, Profit and Revenue, page-5

I suspect B2B sales decrease in order to have enough supply for the B2C market. With VesiSorb, Pastilles/Gummies coming to fruition to the market imminently.

Fantastic results, to post a healthy NPAT of $2m whilst rapidly investing substantial amounts into the business production capacity is a testament to management.

Margins increasing substantially is a phenomenal achievement, expecting this number to be closer to 50-55% with vertical brands sales starting up.

New strains on the way, new products, more production capacity and plenty of cash with access to debt if required to continue operations.

I know that there are usually no major movements on news, but surely this profitability and pathway to increased profitability has to have some form of reflection in the SP. At a P/E of 8 and profitability expected to grow, this is a no brainer.

GLTAH (I am very positively skewed here and will digest what negatives to take from it later, but first read is bringing smiles)